CSX Corporation CSX
Verdict: Sell. Fair value $34.65 against a price of $35.91 on 6 Jan 2026, 4% below the price.
In plain words
The case for: Wide competitive moat provides durability. Market leadership enables pricing power.
The case against: Revenue has declined for two consecutive years, from $14.85B in 2022 to $14.54B in 2024. Net Income....
Main risks
- Negative Return on Incremental Invested Capital (ROIIC): The calculated -5.8% ROIIC is a severe red flag, suggesting that capital invested over the past three years has destroyed value, as operating profits have declined despite significant reinvestment.
- Deteriorating Top and Bottom Lines: Revenue has declined for two consecutive years from its 2022 peak. Net Income and Free Cash Flow show a more pronounced downward trend, with TTM FCF ($1.55B) at less than half the levels of 2021-2023.
- High and Potentially Inefficient CapEx: TTM CapEx of $3.06B is substantial, consuming ~66% of TTM Operating Cash Flow. In the context of negative revenue growth and a negative ROIIC, this level of spending raises serious questions about capital allocation efficiency and potential 'empire building'.
- Valuation prices in optimistic scenario (limited margin for error)
- Overhang: Uncertainty surrounding the competitive landscape due to ongoing Class I railroad merger d...
- Market volatility